ライフサイエンスコーパス: cardiac monitoring

1 specific usual care (short-duration external cardiac monitoring).

2 presence or absence of post-index ambulatory cardiac monitoring.

3 red patient-level factors in the adequacy of cardiac monitoring.

4 large proportion of patients had suboptimal cardiac monitoring.

5 diac comorbidities was not a determinant for cardiac monitoring.

6 d with adjuvant trastuzumab require adequate cardiac monitoring.

7 versus non-RCC or in trials with or without cardiac monitoring.

8 Administration and manufacturer recommended cardiac monitoring.

9 safe at reduced doses if administered under cardiac monitoring.

10 sion tool to identify patients for prolonged cardiac monitoring.

11 who may benefit from more intense, long-term cardiac monitoring.

12 Of the variance in the adequacy of cardiac monitoring, 15.3% was attributable to physician

13 Increasing the low utilization of cardiac monitoring after stroke could identify undiagnos

14 the advantages of this sensor, we conducted cardiac monitoring alongside benchmarks such as the elec

15 total of 373 patients receiving conventional cardiac monitoring and 123 patients receiving ICM.

16 diac activity and are potentially useful for cardiac monitoring and diagnosis.

17 cts, avoiding the requirement for continuous cardiac monitoring and ensuring applicability across div

18 We describe the patterns of cardiac monitoring and evaluate factors associated with

19 Continuous and reliable cardiac monitoring and pacing of rodent and porcine hear

20 tive clinical studies that incorporate close cardiac monitoring and standardized follow-up in patient

21 tform for adhesive bioelectronic devices for cardiac monitoring and treatment.

22 Cardiac MRI, continuous cardiac monitoring, and biomarkers are important diagnos

23 Chemotherapy, trastuzumab use, cardiac monitoring, and comorbidities were identified by

24 Pharmacotherapy and cardiac monitoring are effective in the management of ca

25 versible, efforts to improve the adequacy of cardiac monitoring are needed, particularly in vulnerabl

26 CE stroke etiology and NDAF after prolonged cardiac monitoring, as well as a composite outcome of MA

27 fying patients who may benefit from enhanced cardiac monitoring because of increased risk.

28 the ICM cohort compared to the conventional cardiac monitoring cohort (21.1% vs 7.5%, p < 0.001).

29 have required more stringent and consistent cardiac monitoring criteria and excluded patients with a

30 All the patients received an implantable cardiac monitoring device to detect atrial tachyarrhythm

31 k contributes to reliable, low-cost wearable cardiac monitoring due to accurate performance and usage

32 n-Hodgkin lymphoma and stresses the need for cardiac monitoring during and after chemotherapy.

33 cardiomyopathy, necessitating imaging-based cardiac monitoring during treatment.

34 ote monitoring systems facilitate continuous cardiac monitoring, early detection of diseases, and pro

35 The additive value of prolonged cardiac monitoring for subclinical atrial fibrillation d

36 The utility of noninvasive cardiac monitoring for symptom-rhythm correlation may be

37 ies for cryptogenic stroke include long-term cardiac monitoring, further investigation for structural

38 sought to evaluate the impact of implantable cardiac monitoring (ICM) in the prevention of stroke rec

39 hese findings highlight the need for ongoing cardiac monitoring in these patients, regardless of pree

40 iable model, factors associated with optimal cardiac monitoring included a more recent year of diagno

41 c risk factors before osimertinib treatment, cardiac monitoring, including an assessment of LVEF at b

42 Serial cardiac monitoring, including endomyocardial biopsies, w

43 ble increase of reported heart failures with cardiac monitoring, indicates that this complication oft

44 Remote cardiac monitoring is a promising approach to detect wor

45 rtile range, 3 to 5]), 273 (91.0%) completed cardiac monitoring lasting 24 hours or longer and 259 (8

46 clinical stability, such as level of care or cardiac monitoring, may be amenable to a similar interve

47 coupling between self-related processing and cardiac monitoring observed here implies that, even in t

48 itor treatment to include prospective serial cardiac monitoring of LVEF and serum cardiac biomarkers.

49 Specific recommendations were made for cardiac monitoring of patients who receive medications a

50 lop AF reported as an adverse event or using cardiac monitoring per standard clinical care.

51 Cardiac monitoring, pulse oximetry and capnography are u

52 a multitude of novel technologies for remote cardiac monitoring (RCM) in patients with HF have been d

53 ns and regulatory authorities to re-evaluate cardiac monitoring requirements.

54 Cardiac monitoring should continue in patients receiving

55 e-specific usual care consisting of external cardiac monitoring, such as 12-lead electrocardiograms,

56 With advances in implanted and wearable cardiac monitoring technology, it is now possible to rea

57 biological tissues, facilitating ambulatory cardiac monitoring unhindered by motion artifacts or int

58 es covered in this article include those for cardiac monitoring, ventricular assistance, and cardiac

59 The adequacy of cardiac monitoring was determined.

60 sk group, treatment arm, and compliance with cardiac monitoring were similar for dexrazoxane-exposed

61 We performed rigorous cardiac monitoring, which included obtaining electrocard

62 tient setting and those receiving continuous cardiac monitoring with ICM during the last 3 years.

63 omes between patients receiving conventional cardiac monitoring with repeated 24-hour Holter-monitori